Prange Group and Adragos Pharma to Acquire Sterile Pharmaceutical Production Site

The Fresenius Kabi manufacturing site is in Halden, Norway.


November 15, 2023

3 Min Read
Two pharma companies to acquire Fresenius Kabi site in Norway.
As part of the agreement, Fresenius Kabi will strike a long-term supply agreement for products manufactured at the Halden site. Image courtesy of Adragos Pharma

Prange Group and its affiliate Adragos Pharma have signed agreements with Fresenius Kabi for the acquisition of the leading sterile pharmaceutical production site in Halden, Norway.

As part of the transaction, Fresenius Kabi will strike a long-term supply agreement for products manufactured at the Halden site. This acquisition marks a significant milestone for both the Prange Group and Adragos Pharma expanding their global presence and adding significant capacity for sterile liquid manufacturing. 

“Our collaboration with Fresenius Kabi is a strategic step that resonates with Prange Group's commitment to quality and reliability in supplying our customers and in caring for patients globally," said Otto Prange, chairman of the Prange Group. "Through our partnership with Adragos Pharma, we are set to enhance the potential of the Halden site, which is a testament to the dedication of Halden’s workforce. Recognizing the value of our employees, we are dedicated to fostering their expertise, ensuring that the legacy and integrity of the site continue to thrive.” 

The Halden site is one of the largest and most advanced sterile production facilities in Northern Europe. The state-of-the-art capabilities include the production of IV bags, ampoules, blow-fill-seal technology, and other pharmaceutical dosage forms. The site was not only a cornerstone of Fresenius Kabi's manufacturing capabilities in the Nordics, but already caters to other prominent pharma customers as a contract manufacturer. 

The Prange Group is a leading German family office with a long track record of successfully investing in and growing pharmaceutical companies and CDMOs. The Prange Group was invested in Adragos Pharma from the beginning and remains a cornerstone shareholder, reflecting a long-term commitment to the sector. 

Adragos Pharma has gained attention as Europe’s fastest-growing CDMO and received several awards in recent years. Central to Adragos Pharma’s growth is a strong emphasis on customer service and focus on highest manufacturing standards from production sites in Europe and Japan. 

“The inclusion of the Halden site into Adragos Pharma’s network is a fantastic addition to our network. Halden has a broad range of technologies and offers considerable expansion space that allows us to tailor our services to the specific needs of our customers. We will be positioning the site as one of Europe's premier sterile production facilities," said Dr. Andreas Raabe, CEO, Adragos Pharma’s.

Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Scandinavian investment firm, and Prange Group, a diversified leading German family office. Adragos Pharma has three production sites in France, Germany, and Japan and a development center in Greece. 

Dr. Hans-Christian Meyer, SVP Operations, at Fresenius Kabi stated, “This divestiture reflects our strategic decision to optimize our network and focus on our core areas of expertise. We are confident that the Prange Group together with Adragos Pharma are the right partners to carry forward the legacy of the Halden site.” 

About the Author(s)


Informa Markets Engineering

The Informa Markets Engineering network of B2B media sites includes Design News, Battery Technology, Medical Device & Diagnostic Industry (MD+DI), Packaging Digest, PlasticsToday, and Powder & Bulk Solids.

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like